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ABSTRACT
Objectives: Elizabethkingia meningoseptica has been known to infect the immunocompromised, preterm children, those exposed to antibiotics in 
critical care units, and those with comorbidities. Multidrug resistance seen in E. meningoseptica makes it daunting to choose the right antimicrobial 
agents for treating infections caused by this organism. The present study was undertaken to establish the incidence of E. meningoseptica infections, 
to investigate the clinical features and risk factors associated with these infections, and to study the antimicrobial susceptibility pattern of 
E. meningoseptica isolates over 2 years.
Methods: Medical records of the patient positive for E. meningoseptica from January 2015 to December 2016 were studied retrospectively. The 
demographic and clinical data of the patients and the antibiotic sensitivity patterns were collected and analyzed.
Results: E. meningoseptica was isolated from 13 patients. The mean age was 71.09 years with males being more frequently infected (81.8%). 
Maximum isolates were from blood (38.5%) with sepsis being the final diagnosis in 53.8% of the patients, followed by respiratory tract infection 
(46.1%). Two pediatric patients presented with both sepsis and meningitis. Nine patients (69.2%) recovered, and death occurred in four patients 
(30.8%). Susceptibility testing revealed 100% in vitro resistance to most of the antibiotics such as amikacin, aztreonam, cefepime, ceftazidime, 
colistin, gentamicin, meropenem, and polymyxin B which are used to treat Gram-negative bacterial infections. The isolates were most susceptible to 
minocycline and piperacillin.
Conclusion: E. meningoseptica is an emerging pathogen and is being isolated more frequently now. An expeditious and prompt institution of 
appropriate therapy is essential because of its inherent resistance to many antimicrobial agents commonly used to treat infections caused by Gram-
negative bacteria.
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INTRODUCTION
Elizabethkingia meningoseptica is a Gram-negative, ubiquitous, non-
fermenting, fastidious, obligate aerobic bacillus [1,2]. It has been 
recognized as a threat to patients in critical care areas because of its 
multidrug-resistant phenotype and its capability to adapt to various 
biospheres. It is distributed widely in the hospitals and has been 
isolated in the hospital environment in water supplies, disinfectants, 
and medical devices. The virulence of this organism includes the 
propensity to form biofilms, intracellular invasion, and the ability to 
survive for long periods in moist environments [3-7].
The incidence of E. meningoseptica infections has been increasing 
over the past decade. Patients at high risk of E. meningoseptica 
infection include preterm children, the immune-compromised, those 
exposed to antibiotics in critical care units, the presence of underlying 
diseases, use of central venous catheters, and other invasive medical 
devices [8,9]. E. meningoseptica exhibits chromosomal and plasmid-
mediated resistance to many antimicrobial agents which are used to 
treat Gram-negative bacterial infections such as aminoglycosides and 
extended-spectrum beta-lactam antibiotics but is susceptible to some 
agents such as cotrimoxazole, fluoroquinolones, and vancomycin 
which are used for Gram-positive bacteria [10-12]. Choosing the right 
antimicrobial agents for patients with E. meningoseptica infections 
is difficult because of the lack of interpretive minimum inhibitory 
concentration of antibiotics for E. meningoseptica, the lack of analysis 
of clinical response, and choices of antimicrobial agents in the 
literature [11,13]. Patients with E. meningoseptica bacteremia have the 
poor prognosis, and the use of inappropriate antibiotics can further 
complicate the situation. Hence, it is essential for proper antimicrobial 
susceptibility testing before choosing the antimicrobial agents.
In the past decade, we have observed that the number of patients with 
E. meningoseptica infections is increasing. This study retrospectively 
reviewed the epidemiology, risk factors, clinical features, and 
antimicrobial resistance patterns associated with this E. meningoseptica 
infections in our geographical area over 2 years period. Furthermore, 
the antimicrobial susceptibility pattern of the isolates was also 
analyzed.
METHODS
This study was a retrospective study conducted in an 850-bed 
referral hospital in Mangalore after approval from the institutional 
ethics committee. All clinical samples positive for E. meningoseptica 
from January 2015 to December 2016 were included in this study. 
The details of the patients were obtained from the Medical Records 
Department. Demographic and clinical data including age, gender, and 
clinical manifestations were noted. Besides, information on underlying 
diseases and other associated symptoms during the episode, type of 
infection, use of invasive procedures, duration of intensive care unit 
stay, and the outcomes was obtained and analyzed.
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Identification and antimicrobial sensitivity testing for the blood 
culture isolates were done in the Vitek 2 automated system. 
Antimicrobial sensitivity testing for isolates from other specimens 
was done by Kirby–Bauer disc diffusion method. The interpretation 
of antibiotic sensitivity tests was done according to standards for the 
non-Enterobacteriaceae, set by the Clinical and Laboratory Standards 
Institute.
RESULTS AND DISCUSSION
In this retrospective study of 2 years’ duration from January 2015 to 
December 2016, E. meningoseptica was isolated from 13 patients. The 
bacteria were isolated in four patients from January 2015 to December 
2015 and in nine patients from January 2016 to December 2016. Among 
13 patients, 11 were adults and 2 were neonates. The average age of the 
patients was 71.09 years (excluding the two neonates), varying from 42 
to 92 years. The adult patients included nine males (81.8%) and two 
females (18.2%).
All the adult patients had underlying diseases, including diabetes 
mellitus (DM) (n=6, 54.5%), chronic obstructive pulmonary disease 
(COPD) (n=4, 36.4%), and malignancy (n=3, 22.3%), chronic urinary 
system illness (n=4, 36.4%) which included hydroureteronephrosis, 
renal failure, and urinary tract infection (UTI). Both the neonates 
were male and had no underlying diseases nor were they premature 
(Table 1).
All isolates were obtained from hospitalized patients. Maximum number 
of isolates were from blood (n=5, 38.5%), followed by suction tip (n=3, 
23.1%), bronchoalveolar lavage (BAL) (n=2, 15.4%), and cerebrospinal 
fluid (CSF) (n=2, 15.4%) (Table 1).
Sepsis was the final diagnosis in seven patients (53.8%), whereas six 
patients (46.1%) had lower respiratory tract infection, two patients 
(15.4%) had meningitis, and one patient (7.7%) had wound infection. 
The two pediatric patients presented with both sepsis and meningitis. 
Nine patients (69.2%) recovered from their infective status, whereas 
death occurred among four patients (30.8%). The average duration 
spent in the Intensive Care Unit was found to be 32 days (6–132 days) 
(Table 1).
All the adult patients were on broad-spectrum antimicrobial regimens 
before acquiring the infection.
Six patients (46.2%) had concomitant pathogens isolated along with 
E. meningoseptica. The susceptibility testing revealed in vitro resistance 
to most of the antibiotics used to treat Gram-negative bacteria. The 
susceptibilities of the E. meningoseptica isolates to piperacillin/
tazobactam, cotrimoxazole, and levofloxacin were found to be 60%, 
53.3%, and 38.5%, respectively. The most effective drugs were 
minocycline and piperacillin with 100% susceptibility (Fig. 1)
DISCUSSION
Recent reports indicate an increase in the incidence of infections by 
E. meningoseptica [11]. In our study, although the number of infections 
detected was less, a higher rate was observed in the other half of the 
study period as explained by the increase in the number of cases from 4 
in 2015 to 9 in 2016. The above data indicate that there has been a rise 
in the incidence of infections caused by E. meningoseptica.
E. meningoseptica was isolated from 13 patients, 11 were adults, 
and 2 were neonates. The mean age of the patients was 71.09 years 
(excluding the two neonates), with a strong preference for extremes 
of the period with 81.8% being male patients. In a study conducted in 
Central Taiwan, the mean age of the patient was 72.2 years (excluding 
one child patient), of which 79.9% were male [14].
In our study, all the adult patients had significant underlying diseases, 
the most frequent being DM (54.5%), followed by COPD (36.4%), 
malignancy (22.3%), and chronic urinary tract illness (22.3%). Earlier 
studies have also reported nosocomial infections by E. meningoseptica, 
predominantly in patients with severe underlying diseases, prolonged 
hospitalization, treatment with invasive procedures, prior use of 
broad-spectrum antimicrobials, and associated infections. In a study 
conducted in a Medical Center in Taiwan, the most common underlying 
disease was malignancy (35.6%) followed by DM (25.4%) [11]. The 
possible explanation for our patients to have a higher rate of DM as 
an underlying disease could be because of the higher prevalence of 
this condition in India [15]. E. meningoseptica has been reported to 
cause sepsis, meningitis, and pneumonia among neonates, especially 
Table 1: Clinical profile of 13 patients with E. meningoseptica infections





2016 66 years/Male Sepsis DM, HTN, BA Blood 14,700 6 Improved
2016 60 years/Male LRTI DM, HTN, COPD, 
Aspergilloma, HUN
Sputum 11,500 51 Improved
2016 65 years/Male LRTI Carcinoma lung, Addison’s 
disease, Frontal lobe 
contusion
Aspirate from lung 14,600 11 Improved
2016 42 years/Male Sepsis Multiorgan failure, IHD, 
Pancreatic pseudocyst
Blood 20,100 10 Expired
2016 75 years/Male LRTI DM, HTN, chronic renal 
failure, LV dysfunction
ET suction tip 20,100 16 Expired
2016 92 years/Male Sepsis, wound 
infection
DM, HTN, Carcinoma 
colon, COPD
Swab 20,600 42 Expired
2016 83 years/Female LRTI DM, HTN, BA, CCF, IHD, GB 





2016 3 days/Male Sepsis, meningitis none Blood, CSF 18,200 14 Improved
2016 17 days/Male Sepsis, meningitis none Blood, CSF 16,400 28 Improved
2016 73 years/Male LRTI COPD, PTB, bronchiectasis BAL 20,000 12 Improved
2016 79 years/Male Sepsis Subdural hemorrhage Catheter tip 20,900 132 Improved
2015 70 years/Male Sepsis DM, COPD, Ca. colon, renal 
failure
ET catheter tip 7,800 17 Improved
2015 77 years/Female LRTI HTN, IHD, PTB, pneumonia BAL 17,000 19 Improved
DM: Diabetes mellitus, HTN: Hypertension, COPD: Chronic obstructive pulmonary disease, BA: Bronchial asthma, HUN: Hydroureteronephrosis, IHD: Ischemic heart 
disease, CCF: Congestive cardiac failure, GB syndrome: Guillain–Barre syndrome, UTI: Urinary tract infection, PTB: Pulmonary tuberculosis, BAL: Bronchoalveolar 
lavage, CSF: Cerebrospinal fluid, ET-Endotracheal. E. meningoseptica: Elizabethkingia meningoseptica
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premature infants [1,16]. In our study, E. meningoseptica was isolated 
from two neonates, both males with sepsis and meningitis. However, 
the neonates had no underlying disease nor were they premature.
The predominant source for culture in our study for most of the 
E.  meningoseptica isolates was from blood (38.5%), followed by suction 
tip (23.1%), BAL (15.4%), and CSF (15.4%). In a study conducted by 
Chang et al., the primary source was blood (48.7%) followed by sputum 
(41%) [14]. Another study conducted in a Trauma Center in New Delhi 
showed that the primary source for culture was BAL (70%), followed 
by blood (22%) and CSF (4%) [17]. Various studies have described 
E. meningoseptica as an etiological agent of meningitis, sepsis, pneumonia, 
endocarditis, bacteremia, cellulitis, wound infection, endophthalmitis, 
keratitis, and UTI [1,18-21]. In our study, sepsis was found to be the 
diagnosis in 53.8% of patients, followed by lower respiratory tract 
infection (46.1%), meningitis (15.4%), and wound infection (7.7%). 
All the adult patients in our study were on broad-spectrum antibiotics 
such as meropenem and third-generation cephalosporins before 
acquiring the infection. This observation is comparable to the results 
obtained in a survey conducted by Rastogi et al., wherein all the 
patients too were on broad-spectrum antibiotics before procuring the 
infection [17]. Thus, we can consider that the increased use of broad-
spectrum antibiotics against other multidrug-resistant Gram-negative 
organisms such as Acinetobacter spp. and Klebsiella pneumoniae could 
lead to superinfection with E. meningoseptica [22].
Several studies have confirmed E. meningoseptica to be a common 
contaminant of various medical devices such as mechanical 
ventilators, intubation tubes, syringes, intravenous catheters, and 
prosthetic valves [6,23-25]. In our study, these bacteria were isolated 
from patients who were on mechanical ventilators (25.9%), intravenous 
catheters (22.2%), intubation tubes (24.8%), and bronchoscopy 
endotracheal tubes (11.1%). The infections due to these bacteria in our 
study cannot be attributed to contaminated devices only as no attempt 
was made to isolate the organism from the medical devices. Precautionary 
measures should be used in the treatment of patients on mechanical 
ventilators and those who are transferred to acute care hospitals with 
infections caused by this organism as suggested by Weaver et al. [26].
Infections with E. meningoseptica were associated with poor outcome, 
with mortality varying from 23% to 52% as given by several studies [11]. 
The risk factors for the poor outcome could be the presence of central 
venous line infection, inappropriate use of antibiotics, prolonged 
hospital stay, and the possible presence of a high biofilm-forming 
organism [3]. The 28-day mortality in a study conducted by Lin et al. 
was found to be 41% [13]. In our study, the mortality was 30.8% with 
the patients predominantly suffering from sepsis and lower respiratory 
tract infections, with only 69.2% of the patients recovering from their 
infective status. All the patients in our study had prolonged hospital 
stay with a range from 6 to 132 days (mean=32 days). Our findings are 
similar to the result of Lin et al. where the mean duration of hospital stay 
was 32 days (range 13–99 days) [18]. However, in a study conducted 
during an outbreak of E. meningoseptica in London, the mean duration 
of hospital stay was found to be 17 days (range 4–35 days) [27]. Six 
patients (46.2%) in our study had concomitant pathogens such as 
Pseudomonas aeruginosa, K. pneumoniae, Acinetobacter baumannii, 
Proteus mirabilis, Sphingomonas paucimobilis, Stenotrophomonas 
maltophilia, and methicillin-resistant Staphylococcus aureus. The 
isolation of concomitant pathogens makes it difficult to explain the 
pathogenic role of E. meningoseptica.
The antibiotic sensitivity pattern of E. meningoseptica varies across 
the reported literature. The organism was said to be resistant to most 
of the β-lactam antibiotics including carbapenems and aztreonam, 
the aminoglycoside group of drugs and chloramphenicol, but was 
susceptible to drugs such as cotrimoxazole, fluoroquinolones, 
minocycline, tigecycline, and piperacillin [7,9,11,12,14,25]. Studies 
investigating the resistance of E. meningoseptica have discovered this 
unusual antimicrobial sensitivity pattern to be due to its production of 
metallo-β-lactamases coded by BlaB and Bla (GOB) genes, conferring 
the ability to degrade most of the β-lactam antibiotics, thereby 
restraining their usefulness as a therapeutic option [10]. This high-
level antibiotic resistance may be the reason for the appearance 
of this organism in our patients who were all on broad-spectrum 
antibiotics. The antibiotic susceptibility testing by Kirby–Bauer disc 
diffusion method revealed resistance to amikacin (100%), gentamicin 
(100%), aztreonam (100%), cefepime (100%), ceftazidime (100%), 
meropenem (100%), imipenem (93.8%), polymyxin B (100%), colistin 
(100%), and tigecycline (50%). The susceptibilities of our isolates to 
piperacillin/tazobactam, cotrimoxazole, and levofloxacin were found 
to be 60%, 53.3%, and 38.5%, respectively. The most effective drugs 
were minocycline and piperacillin with 100% susceptibility. Previous 
reports have also demonstrated 100% susceptibility of the bacteria 
toward minocycline [1,14].
To conclude, E. meningoseptica is an emerging pathogen and is being 
isolated more frequently now, especially in patients with severe 
underlying diseases, prolonged hospitalization, treatment with invasive 
procedures, and prior use of broad-spectrum antimicrobials. Rapid 
diagnosis and timely institution of appropriate therapy are essential 
Fig. 1: Antibiotic susceptibility pattern of Elizabethkingia meningoseptica
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because of its inherent resistance to many antimicrobial agents 
commonly used to treat infections caused by Gram-negative bacteria.
CONCLUSION
E. meningoseptica was isolated from 13 patients. The mean age was 
71.09 years with males being more frequently infected (81.8%). 
Maximum isolates were from blood (38.5%) with sepsis being the 
final diagnosis in 53.8% of the patients, followed by respiratory 
tract infection (46.1%). Two pediatric patients presented with both 
sepsis and meningitis. Nine patients (69.2%) recovered, and death 
occurred in 4 patients (30.8%). Susceptibility testing revealed 
100% in vitro resistance to most of the antibiotics such as amikacin, 
aztreonam, cefepime, ceftazidime, colistin, gentamicin, meropenem, 
and polymyxin B which are used to treat Gram-negative bacterial 
infections. The isolates were most susceptible to minocycline and 
piperacillin. E. meningoseptica is an emerging pathogen and is being 
isolated more frequently now. An expeditious and prompt institution 
of appropriate therapy is essential because of its inherent resistance to 
many antimicrobial agents commonly used to treat infections caused by 
Gram-negative bacteria.
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